Evolution in the Care of NSCLC: Keeping Pace With Today’s Best Practices

Watch this CME-certified on-demand Webcast of a CCO symposium from ASCO 2019 where experts discuss best practices in the rapidly evolving treatment paradigm across advanced NSCLC.
Edward S. Kim, MD, FACP
Zofia Piotrowska, MD, MHS
Suresh S. Ramalingam, MD
H. Jack West, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: July 8, 2019 Expiration: July 7, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the appropriate molecular markers to guide clinical decisions for patients with advanced-stage NSCLC
  • Integrate into practice the available clinical evidence and expert recommendations after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Plan individualized treatment strategies for patients with NSCLC positive for EGFR mutations, ALK gene rearrangements, BRAF mutations, or high PD-L1 expression, taking into consideration the available data and consensus expert recommendations
  • Appropriately manage treatment-related adverse events associated with targeted agents and immune checkpoint inhibitors used in patients with advanced-stage NSCLC
  • Describe to colleagues the speed of evolution in best practices for the treatment of NSCLC and the need to routinely use resources such as guidelines and tools in selecting treatment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Edward S. Kim, MD, FACP

Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Edward S. Kim, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, Lilly, Merck, and Takeda and funds for research support from AstraZeneca, Genentech, Lilly, and Takeda.
Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received consulting fees from AstraZeneca, Guardant Health, ImmunoGen, Spectrum, and Takeda and funds for research support from AstraZeneca, Novartis, Spectrum, and Takeda.
Suresh S. Ramalingam, MD

Professor of Hematology and Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Suresh S. Ramalingam, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Loxo, Merck, Nektar, Tesaro, and Takeda and funds for research support from AstraZeneca, Bristol-Myers Squibb, Merck, and Syndax.
H. Jack West, MD

Associate Clinical Professor
City of Hope Comprehensive Cancer Center
Duarte, California

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad/Takeda, Bristol-Myers Squibb, Celgene, Genentech/Roche, and Merck and fees for non-CME/CE services from Ariad/Takeda, Genentech/Roche, Lilly, and Merck.


Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has reported that his spouse has ownership interest in and has received salary from AstraZeneca.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with NSCLC.


The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in the treatment of patients with NSCLC.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2019, through July 07, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), download this PDF summarizing HER2, HER3, and TROP2 testing and targeted therapeutics

Mark D. Pegram, MD Michael F. Press, MD, PhD Released: July 30, 2020

From Clinical Care Options (CCO), watch this video featuring expert presentations on new and emerging biomarkers key to lung cancer care

Edward S. Kim, MD, FACP
Program Director
Leora Horn, MD, MSc, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: July 30, 2020 Expired: July 29, 2021

Watch expert faculty discuss updated testing and treatment options for METex14-positive NSCLC in this video from Clinical Care Options (CCO)

D. Ross Camidge, MD, PhD person default Luis Paz-Ares, MD, PhD Karen L. Reckamp, MD, MS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: July 24, 2020 Expired: July 23, 2021

Downloadable PDF resource to aid treatment discussions with patients with advanced NSCLC including capturing their input on goals and preferences, from Clinical Care Options (CCO)

Released: July 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?